Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 2/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | GAPDH | P04406 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20991046 | 1.00 | ADORA2A (0.58) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL13929030 | 1.00 | ADORA2A (0.58) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL21232918 | 1.00 | ADORA2A (0.58) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL12799362 | 1.00 | ADORA2A (0.58) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL12194662 | 1.00 | ADORA2A (0.58) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL14429150 | 0.92 | ADORA2A (0.53) | ADORA2AADORA3ADORA1ADORA2BPI4KA | |
| SCHEMBL20991045 | 0.90 | ADORA2A (0.52) | ADORA2AADORA3ADORA1ADORA2BPI4KA | |
| SCHEMBL1374226 | 0.87 | ADORA2A (0.76) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL12149963 | 0.87 | ADORA2A (0.76) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL21232917 | 0.87 | ADORA2A (0.59) | ADORA2AADORA3ADORA1ADORA2BPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315792-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, LTD. (BB) | 2019-10-17 | — | — | US | disclosed |
| EP-3521297-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | Gilead Pharmasset LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2552203-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2604620-A1 | Modified fluorinated nucleoside analogues | Gilead Pharmasset LLC (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012154321-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120251487-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120245335-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | GILEAD PHARMASSET LLC (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2011123586-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110243886-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | SURLERAUX DOMINIQUE | 2011-10-06 | — | — | US | disclosed |
| EP-2345661-A1 | Modified fluorinated nucleoside analogues | Pharmasset, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2345659-A1 | Modified fluorinated nucleoside analogues | Pharmasset, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110038833-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20090036666-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080253995-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7429572-B2 | Modified fluorinated nucleoside analogues | PHARMASSET, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080070861-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070861-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885ADORA1 182/4885 |
| US-20110243886-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, EIF2AK2 | ADORA2A 608/4885ADORA3 830/4885ADORA1 961/4885 |
| US-20090036666-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885ADORA1 182/4885 |
| US-20190315792-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885ADORA1 182/4885 |
| US-20110038833-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885ADORA1 182/4885 |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885ADORA1 182/4885 |
| US-20120245335-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885ADORA1 182/4885 |
| US-20120251487-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, EIF2AK2 | ADORA2A 608/4885ADORA3 830/4885ADORA1 961/4885 |
| US-20080253995-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADORA3 102/4885ADORA1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.